- Home
- TACT vs ANVS Comparison
TACT vs ANVS Comparison
Compare TACT & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TACT | ANVS |
|---|---|---|
| Founded | 1996 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.7M | 50.4M |
| IPO Year | 1996 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TACT | ANVS |
|---|---|---|
| Price | $4.65 | $1.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.50 |
| AVG Volume (30 Days) | 14.0K | ★ 930.6K |
| Earning Date | 11-09-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.88 | 39.39 |
| EPS | ★ 0.07 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.17 | N/A |
| Revenue Next Year | $3.74 | N/A |
| P/E Ratio | $65.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.06 | $1.04 |
| 52 Week High | $6.02 | $5.50 |
Technical Indicators
Market Signals| Indicator | TACT | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 37.83 | 43.07 |
| Support Level | $3.30 | $1.04 |
| Resistance Level | $5.42 | $1.43 |
| Average True Range (ATR) | 0.25 | 0.09 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 10.07 | 28.81 |
Price Performance
Historical ComparisonAbout TACT TransAct Technologies Incorporated
Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.